GlobeNewswire by notified

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

Share

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration

SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.

“FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro. “We are proud to support AviadoBio and the team at Mazowiecki Szpital Bródnowski Hospital, as well as other clinical trial sites to come in Europe and the United States.”

More information about the ASPIRE-FTD study can be found at https://clinicaltrials.gov/study/NCT06064890.

About Frontotemporal Dementia with Progranulin Mutations (FTD-GRN)

FTD is a devastating form of early-onset dementia that typically leads to death within seven to 13 years of symptom onset and three to 10 years from diagnosis.1,2 People with FTD commonly experience personality changes, behavioral disturbance, loss of language, apathy, and reduced mobility.3

FTD is a leading cause of dementia in people under the age of 654 with an estimated prevalence at any one time of up to 4.6 cases per 1,000 people.5 FTD typically strikes younger than Alzheimer’s disease and the majority of FTD cases occur between 45 and 68 years of age.6,7 Given the early onset, FTD can have a substantially greater impact on work, family, and finances than Alzheimer’s disease.8 Genetic FTD cases account for about one-third of cases and are associated with autosomal dominant mutations in three genes, including the GRN (progranulin) gene.9 Approximately 11,000 people in the U.S. and EU5 are living with FTD-GRN with approximately 2,200 new cases per year. 1,10 Some FTD cases may be misidentified, and diagnostic delay is common. As disease education, genetics knowledge, and research and treatment options grow, these numbers are expected to increase.

________________________
1 Onyike CU. Neuroepidemiology. 2011;37:166–167
2 Riedl L et al. Neuropsychiatr Dis Treat. 2014;10:297–310
3 Pressman P and Miller BL. Biol Psychiatry. 2014;75(7):574–581
4 Hendriks S, Peetoom K, Bakker C, et al. Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurol. 2021;78(9):1080–1090. doi:10.1001/jamaneurol.2021.216
5 Hogan DB et al. Can J Neurol Sci. 2016;43 (Suppl 1):S96–S109
6 Moore KM et al. Lancet Neurol. 19(2):145–156
7 Kansal K et al. Dement Geriatr Cogn Disord. 2016;41:109–122
8 Galvin JE et al. Neurology. 89(20):2049–2056
9 Young JJ et al. Ther Adv Psychopharmacol. 2018;8(1):33–48
10 Kuang, L., et. al. Frontotemporal dementia non-sense mutation of progranulin rescued by aminoglycosides. Human Molecular Genetics 2020;29(4):624-634


About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company’s flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

This press release contains forward-looking statements within the context of the federal securities laws, which may include the Company’s expectation for the future market of its products and services, and other performance and results. These forward-looking statements are based on management’s current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s products and services; the Company’s ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company’s products and services in their delivery of therapies; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company’s ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which has been filed with the Securities and Exchange Commission. The Company does not assume any obligation to update these forward-looking statements.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Udnævnelse af ny CFO24.5.2024 20:05:00 CEST | pressemeddelelse

MEDDELELSE NR. 269 Udnævnelse af ny CFO Bestyrelsen i ChemoMetec har med virkning fra 1. juli 2024 ansat Kim Nicolajsen som ny CFO. Kim Nicolajsen kommer fra en tilsvarende stilling som CFO i den familieejede virksomhed Rohde Nielsen. Han er statsautoriseret revisor og har tidligere arbejdet for KPMG og EY. Bestyrelsen har samtidig indgået aftale med selskabets nuværende CFO Niels Høy Nielsen om, at han fratræder sin stilling samtidig med Kim Nicolajsens tiltræden. Bestyrelsen vil gerne takke Niels Høy Nielsen for hans indsats i ChemoMetec og for det gode samarbejde. Direktionen i ChemoMetec vil herefter bestå af CEO Martin Helbo Behrens og CFO Kim Nicolajsen. Yderligere oplysninger Bestyrelsesformand Niels Thestrup Telefon: (+45) 3370 2000 CEO Martin Helbo Behrens Telefon: (+45) 4813 1020 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrumenter til celletælling og en lang række andre målinger. ChemoMetecs instrumenter markedsføres globalt inden for blandt andet f

Appointment of new CFO24.5.2024 20:05:00 CEST | Press release

ANNOUNCEMENT NO. 269 Appointment of new CFO The board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec. For further information Chairman of the Board Niels Thestrup Phone: (+45) 3370 2000 CEO Martin Helbo Behrens Phone: (+45) 4813 1020 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s i

Interim Report January – March 202424.5.2024 19:35:00 CEST | Press release

First quarter 2024 (compared to first quarter 2023) Net sales for the quarter amounted to MSEK 13 (13)Gross margin for the quarter decreased to 67% (74%)Operating loss amounted to MSEK -14 (-14)Earnings per share before and after dilution decreased to SEK 0.00 (-0.12) The report for January – March 2024 is available in its entirety on the following address: https://www.anoto.com/investors/reports/ For further information contact: Kevin Adeson, Chairman of the Board of Directors For more information about Anoto, visit www.anoto.com or email ir@anoto.com Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, 116 74 Stockholm This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication on 24 May 2024 at 19:30 CEST. About Anoto Group Anoto is a publicly held Swedish technology company known globally for innovation in the area of infor

Delårsrapport för januari – mars 202424.5.2024 19:35:00 CEST | Pressemelding

Första kvartalet 2024 (jämfört med första kvartalet 2023) Nettoomsättningen uppgick till MSEK 13 (13)Bruttomarginalen minskade till 67 % (74 %)Rörelseförlusten uppgick till MSEK -14 (-14)Resultat per aktie före och efter utspädning uppgick till SEK 0.00 (-0.12) Delårsrapporten för januari-mars 2024 finns tillgänglig i dess helhet på följande adress: https://www.anoto.com/investors/reports/ För ytterligare information kontakta: Kevin Adeson, Styrelseordförande För mer information om Anoto, besök www.anoto.com eller email ir@anoto.com Anoto Group AB (publ), Org.nr 556532-3929, Flaggan 1165, 116 74 Stockholm Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom ovanstående kontaktpersons försorg för offentliggörande den 24 maj 2024, kl. 19:30 CEST. Om Anoto Anoto är ett börsnoterat svenskt teknikföretag, som är känt i hela världen för innovationer rörande informationsrika mönster

HiddenA line styled icon from Orion Icon Library.Eye